Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen Closes $26M Sentigen Acquisition

NEW YORK (GenomeWeb News) — Invitrogen today said it has closed its acquisition of Sentigen Holding.
 
The $25.9 million cash deal was announced in September.
 
Invitrogen paid $3.37 per share for the Phillipsburg, NJ-based company, which will become part of Invitrogen’s Discovery Sciences division, located in Madison, Wis.
 
With the acquisition, Invitrogen picks up Sentigen’s Tango assay system for protein interaction and GPCR screening and its assay ready cells that pare down the assay process, the company said.
 
At close of the business day Dec. 1, Sentigen had $11 million in cash on hand and cash investments, the company said. At mid-day today Sentigen shares were trading at $3.40.
The Scan

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.

Team Presents Cattle Genotype-Tissue Expression Atlas

Using RNA sequences representing thousands of cattle samples, researchers looked at relationships between cattle genotype and tissue expression in Nature Genetics.

Researchers Map Recombination in Khoe-San Population

With whole-genome sequences for dozens of individuals from the Nama population, researchers saw in Genome Biology fine-scale recombination patterns that clustered outside of other populations.

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.